238 related articles for article (PubMed ID: 35047111)
1. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
Heffernan MLR; Herman LW; Brown S; Jones PG; Shao L; Hewitt MC; Campbell JE; Dedic N; Hopkins SC; Koblan KS; Xie L
ACS Med Chem Lett; 2022 Jan; 13(1):92-98. PubMed ID: 35047111
[TBL] [Abstract][Full Text] [Related]
2. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
Yang SM; Ghoshal A; Hubbard JM; Gackière F; Teyssié R; Neale SA; Hopkins SC; Koblan KS; Bristow LJ; Dedic N
Neuropsychopharmacology; 2024 Jun; 49(7):1091-1103. PubMed ID: 38110609
[TBL] [Abstract][Full Text] [Related]
3. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
[TBL] [Abstract][Full Text] [Related]
4. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.
Synan C; Bowen C; Heal DJ; Froger-Colléaux C; Beardsley PM; Dedic N; Hopkins SC; Campbell U; Koblan KS
Drug Alcohol Depend; 2022 Feb; 231():109261. PubMed ID: 35033729
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
[TBL] [Abstract][Full Text] [Related]
6. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
Højlund M; Correll CU
Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
[TBL] [Abstract][Full Text] [Related]
8. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT
Xiao G; Chen YL; Dedic N; Xie L; Koblan KS; Galluppi GR
Pharm Res; 2022 May; 39(5):837-850. PubMed ID: 35484370
[TBL] [Abstract][Full Text] [Related]
9. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potential TAAR1 agonist targeting neurological and psychiatric disorders: An in silico approach.
Garisetti V; Dhanabalan AK; Dasararaju G
Int J Biol Macromol; 2024 Apr; 264(Pt 2):130528. PubMed ID: 38431013
[TBL] [Abstract][Full Text] [Related]
11. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Dedic N; Wang L; Hajos-Korcsok E; Hecksher-Sørensen J; Roostalu U; Vickers SP; Wu S; Anacker C; Synan C; Jones PG; Milanovic S; Hopkins SC; Bristow LJ; Koblan KS
Mol Metab; 2024 Feb; 80():101883. PubMed ID: 38237896
[TBL] [Abstract][Full Text] [Related]
12. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders.
Halff EF; Rutigliano G; Garcia-Hidalgo A; Howes OD
Trends Neurosci; 2023 Jan; 46(1):60-74. PubMed ID: 36369028
[TBL] [Abstract][Full Text] [Related]
13. Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.
Kuvarzin SR; Sukhanov I; Onokhin K; Zakharov K; Gainetdinov RR
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509616
[TBL] [Abstract][Full Text] [Related]
14. Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.
Feemster JC; Westerland SM; Gossard TR; Steele TA; Timm PC; Jagielski JT; Strainis E; McCarter SJ; Hopkins SC; Koblan KS; St Louis EK
Sleep Med; 2023 Jan; 101():578-586. PubMed ID: 36584503
[TBL] [Abstract][Full Text] [Related]
15. Trace Amine Associate Receptor 1 (TAAR1) as a New Target for the Treatment of Cognitive Dysfunction in Alzheimer's Disease.
Leo D; Targa G; Espinoza S; Villers A; Gainetdinov RR; Ris L
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887159
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.
Le GH; Gillissie ES; Rhee TG; Cao B; Alnefeesi Y; Guo Z; Di Vincenzo JD; Jawad MY; March AM; Ramachandra R; Lui LMW; McIntyre RS
Expert Opin Investig Drugs; 2023 May; 32(5):401-415. PubMed ID: 37096491
[TBL] [Abstract][Full Text] [Related]
17. TAAR1 as an emerging target for the treatment of psychiatric disorders.
Liu J; Wu R; Li JX
Pharmacol Ther; 2024 Jan; 253():108580. PubMed ID: 38142862
[TBL] [Abstract][Full Text] [Related]
18. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.
Revel FG; Moreau JL; Gainetdinov RR; Ferragud A; Velázquez-Sánchez C; Sotnikova TD; Morairty SR; Harmeier A; Groebke Zbinden K; Norcross RD; Bradaia A; Kilduff TS; Biemans B; Pouzet B; Caron MG; Canales JJ; Wallace TL; Wettstein JG; Hoener MC
Biol Psychiatry; 2012 Dec; 72(11):934-42. PubMed ID: 22705041
[TBL] [Abstract][Full Text] [Related]
19. TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT
Saarinen M; Mantas I; Flais I; Ågren R; Sahlholm K; Millan MJ; Svenningsson P
Neuropsychopharmacology; 2022 Dec; 47(13):2319-2329. PubMed ID: 36100653
[TBL] [Abstract][Full Text] [Related]
20. Trace amine associated receptor 1: predicted effects of single nucleotide variants on structure-function in geographically diverse populations.
Shajan B; Marri S; Bastiampillai T; Gregory KJ; Hellyer SD; Nair PC
Hum Genomics; 2024 Jun; 18(1):61. PubMed ID: 38863077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]